Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94649 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL6165713 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL3015647 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL8893832 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL8356788 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL8915954 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL4653423 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL3034401 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL4363618 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 | |
| SCHEMBL5736840 | 1.00 | NAAA (0.61) | NAAATSHREPHX1HCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0444199-B1 | ASCORBIC ACID DERIVATIVES | NIPPON HYPOX LAB INC (JP) | 1995-12-13 | — | — | EP | claimed |
| US-5194445-A | Elimination of active oxygen species produced during ischemia-reperfusion process | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1993-03-16 | — | — | US | claimed |
| EP-0444199-A1 | ASCORBIC ACID DERIVATIVES | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1991-09-04 | — | — | EP | claimed |
| US-7129256-B2 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| EP-0933379-B1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20030191120-A1 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1321151-A1 | ANTIPARKINSONISM DRUGS | SHIONOGI & CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
| US-6319902-B1 | TO ACTIVATE THE CENTRAL NERVOUS SYSTEM, SUCH AS, FOR EXAMPLE, SUSTAINED ACETYLCHOLINE RELEASING ACTION, ANTI-RESERPINE ACTION AND LOCOMOTOR INCREMENT | SHIONOGI & CO., LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-0933379-A1 | NOVEL PEPTIDE DERIVATIVES HAVING THIAZOLYL-ALANINE RESIDUE | SHIONOGI & CO., LTD. (JP) | 1999-08-04 | — | — | EP | disclosed |
| US-5670563-A | ORGANOTIN COMPOUND, PHOSPHORUS COMPOUND | CIBA-SPECIALTY CHEMICALS CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0444199-B1 | ASCORBIC ACID DERIVATIVES | NIPPON HYPOX LAB INC (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5194445-A | Elimination of active oxygen species produced during ischemia-reperfusion process | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0444199-A1 | ASCORBIC ACID DERIVATIVES | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4384980-A | COLOR CHANGE UPON EXPOSURE TO ACTINIC RADIATION OR THERMAL ANNEALING | ALLIED CORPORATION (US) | 1983-05-24 | — | — | US | disclosed |
| US-4285856-A | IMIDOTHIOESTERS | CIBA-GEIGY CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| US-4238352-A | CONJUGATED DIYNES WITH SULFONATE, URETHANE, OR HYDROXY GROUPS | ALLIED CHEMICAL CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
| US-4235108-A | THERMOCHROMIC | ALLIED CHEMICAL CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
| US-4189399-A | UNDERGOES COLOR CHANGE WHEN EXPOSED TO ACTINIC RADIATION OR ANNEALING | ALLIED CHEMICAL CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191120-A1 | Antiparkinsonism drugs | PARK7, SNCA, NLN | NAAA 1167/4885TSHR 779/4885EPHX1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.